Results 1 to 10 of about 32,386 (229)

Adalimumab

Drugs, 2006
Adalimumab, a fully human monoclonal antibody, is a tumour necrosis factor antagonist that has been investigated for efficacy in psoriatic arthritis, based on well-established use of the drug in rheumatoid arthritis. In well-controlled Phase III trials, adalimumab (40 mg administered subcutaneously every other week) has shown efficacy in adult patients
Dene, Simpson, Lesley J, Scott
europepmc   +3 more sources

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial

Dermatology and Therapy, 2023
This Summary of Research overviews the results of the VOLTAIRE-X study (NCT03210259), which looked at what happened when people with plaque psoriasis continually took the adalimumab reference product (adalimumab RP; known by the brand name Humira®) or ...
Alan Menter
doaj   +1 more source

Effect of adalimumab on quality of life in patients with active ankylosing spondylitis [PDF]

Xin yixue, 2023
Objective To evaluate the efficacy of adalimumab in improving the quality of life of adult patients with active ankylosing spondylitis （AS）. Methods This was a post-hoc study of the randomized，double-blind controlled clinical trial of adalimumab and ...
Cao Shuangyan, Shao Zhanqin, Gu Jieruo
doaj   +1 more source

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Drugs in R&D, 2023
Background Adalimumab-aqvh/CHS-1420 (YUSIMRYTM) (hereafter referred to as adalimumab-aqvh) was recently approved by the US Food and Drug Administration as a biosimilar for adalimumab.
Yijia Jiang, Taruna Arora, Scott Klakamp, Janice Davis, Yasmin A. Chandrasekher, Glen Young, Yue Du, Bin Yu, Karen J. Miller   +8 more
doaj   +1 more source

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Frontiers in Pharmacology, 2021
Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of this ...
Evelien Moorkens, Brian Godman, Brian Godman, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Mörtenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Vončina, Vera Vlahović Palčevski, Gnosia Achniotou, Juraj Slabý, Leona Popelková, Kateřina Kohoutová, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. Selke, Vasileios Kourafalos, Einar Magnússon, Rannveig Einarsdóttir, Roisín Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greičiūtė-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Øyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Corinne Zara, Vanda Marković-Peković, Nataša Grubiša, Gustaf Befrits, Robert Puckett, Arnold G. Vulto, Arnold G. Vulto   +45 more
doaj   +1 more source

Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease

Frontiers in Pediatrics, 2021
Introduction: Adalimumab is effective in inducing and maintaining remission in children with inflammatory bowel diseases (IBD). Therapeutic drug monitoring is an important strategy to maximize the response rates, but data on the association of serum ...
Marianna Lucafò, Debora Curci, Matteo Bramuzzo, Patrizia Alvisi, Stefano Martelossi, Tania Silvestri, Veronica Guastalla, Flavio Labriola, Gabriele Stocco, Giuliana Decorti, Giuliana Decorti   +10 more
doaj   +1 more source

Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects

Clinical and Translational Science, 2021
This study aimed to demonstrate pharmacokinetic (PK) equivalence of a single dose of the proposed adalimumab biosimilar CT‐P17 to United States‐licensed adalimumab (US‐adalimumab) and European Union‐approved adalimumab (EU‐adalimumab). This double‐blind,
Kyung‐Sang Yu, In‐Jin Jang, Hyeong‐Seok Lim, Jang Hee Hong, Min‐Gul Kim, Min Kyu Park, Doo‐Yeoun Cho, Min Soo Park, Jae Yong Chung, Jong‐Lyul Ghim, SeungHwan Lee, Seok Kyu Yoon, In Sun Kwon, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Jung Bin Cha, Daniel E. Furst, Edward Keystone, Jonathan Kay   +19 more
doaj   +1 more source

Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab

Frontiers in Pharmacology, 2021
Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-
Lei Wang, Lei Wang, Lixiong Liu, Xiaoping Hong, Dongzhou Liu, Zeneng Cheng   +5 more
doaj   +1 more source

Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study

Gut and Liver, 2020
Background/Aims: Studies on long-term outcomes of adalimumab therapy in non-Caucasian patients with ulcerative colitis (UC) are lacking. Methods: We analyzed long-term outcomes of Korean UC patients treated with adalimumab at the Asan Medical Center ...
Eun Hye Oh, Jeongseok Kim, Namseok Ham, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye   +9 more
doaj   +1 more source

Adalimumab in the treatment of cardiac sarcoidosis: Single center case series and narrative literature review

Respiratory Medicine Case Reports, 2022
Background: Tumor necrosis factor (TNF) inhibitors have been used in the treatment of cardiac sarcoidosis, infliximab being the most commonly used.
Jaleel Jerry G. Sweis, Nabil William G. Sweis, Christian Ascoli, Benjamin Levin, Boaz Avitall, Israel Rubinstein, George Kondos, Daniel A. Culver, Marc Judson, Robert Baughman, Dawood Darbar, Wonder Drake, Shiva Shahrara, Leslie T. Cooper, Jr., Nadera J. Sweiss   +14 more
doaj   +1 more source